Cargando…
Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013
Background. The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduction of a vaccine specifically designed for this part of the world. During the first year alone, the number of people who received the vaccine through mass v...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639501/ https://www.ncbi.nlm.nih.gov/pubmed/26553675 http://dx.doi.org/10.1093/cid/civ599 |
_version_ | 1782399924357300224 |
---|---|
author | Diomandé, Fabien V. K. Yaméogo, Téné M. Vannice, Kirsten S. Preziosi, Marie-Pierre Viviani, Simonetta Ouandaogo, Claude-Roger Keita, Modibo Djingarey, Mamoudou H. Mbakuliyemo, Nehemie Akanmori, Bartholomew Dicky Sow, Samba O. Zuber, Patrick L. F. |
author_facet | Diomandé, Fabien V. K. Yaméogo, Téné M. Vannice, Kirsten S. Preziosi, Marie-Pierre Viviani, Simonetta Ouandaogo, Claude-Roger Keita, Modibo Djingarey, Mamoudou H. Mbakuliyemo, Nehemie Akanmori, Bartholomew Dicky Sow, Samba O. Zuber, Patrick L. F. |
author_sort | Diomandé, Fabien V. K. |
collection | PubMed |
description | Background. The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduction of a vaccine specifically designed for this part of the world. During the first year alone, the number of people who received the vaccine through mass vaccination campaigns was several hundredfold higher than that of subjects who participated in the closely monitored clinical trials. Implementation of a system to identify rare but potentially serious vaccine reactions was therefore a high priority in the design and implementation of those campaigns. Methods. National authorities and their technical partners set up effective vaccine pharmacovigilance systems, including conducting active surveillance projects. Results. Implementation of national expert advisory groups to review serious adverse events following immunization in all countries and active monitoring of conditions of interest in 3 early-adopter countries did not identify particular concerns with the safety profile of PsA-TT, which had already provided tremendous public health benefits. Conclusions. Lessons learned from this experience will help to improve preparations for future vaccine introductions in resource-poor settings and capitalize on such efforts to advance vaccine safety systems in the future. |
format | Online Article Text |
id | pubmed-4639501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46395012015-11-12 Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 Diomandé, Fabien V. K. Yaméogo, Téné M. Vannice, Kirsten S. Preziosi, Marie-Pierre Viviani, Simonetta Ouandaogo, Claude-Roger Keita, Modibo Djingarey, Mamoudou H. Mbakuliyemo, Nehemie Akanmori, Bartholomew Dicky Sow, Samba O. Zuber, Patrick L. F. Clin Infect Dis The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Background. The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduction of a vaccine specifically designed for this part of the world. During the first year alone, the number of people who received the vaccine through mass vaccination campaigns was several hundredfold higher than that of subjects who participated in the closely monitored clinical trials. Implementation of a system to identify rare but potentially serious vaccine reactions was therefore a high priority in the design and implementation of those campaigns. Methods. National authorities and their technical partners set up effective vaccine pharmacovigilance systems, including conducting active surveillance projects. Results. Implementation of national expert advisory groups to review serious adverse events following immunization in all countries and active monitoring of conditions of interest in 3 early-adopter countries did not identify particular concerns with the safety profile of PsA-TT, which had already provided tremendous public health benefits. Conclusions. Lessons learned from this experience will help to improve preparations for future vaccine introductions in resource-poor settings and capitalize on such efforts to advance vaccine safety systems in the future. Oxford University Press 2015-11-15 2015-11-09 /pmc/articles/PMC4639501/ /pubmed/26553675 http://dx.doi.org/10.1093/cid/civ599 Text en © 2015 World Health Organization; licensee Oxford Journals. http://creativecommons.org/licenses/by/3.0/igo/legalcode This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL |
spellingShingle | The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Diomandé, Fabien V. K. Yaméogo, Téné M. Vannice, Kirsten S. Preziosi, Marie-Pierre Viviani, Simonetta Ouandaogo, Claude-Roger Keita, Modibo Djingarey, Mamoudou H. Mbakuliyemo, Nehemie Akanmori, Bartholomew Dicky Sow, Samba O. Zuber, Patrick L. F. Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 |
title | Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 |
title_full | Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 |
title_fullStr | Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 |
title_full_unstemmed | Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 |
title_short | Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 |
title_sort | lessons learned from enhancing vaccine pharmacovigilance activities during psa-tt introduction in african countries, 2010–2013 |
topic | The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639501/ https://www.ncbi.nlm.nih.gov/pubmed/26553675 http://dx.doi.org/10.1093/cid/civ599 |
work_keys_str_mv | AT diomandefabienvk lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT yameogotenem lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT vannicekirstens lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT preziosimariepierre lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT vivianisimonetta lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT ouandaogoclauderoger lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT keitamodibo lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT djingareymamoudouh lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT mbakuliyemonehemie lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT akanmoribartholomewdicky lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT sowsambao lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 AT zuberpatricklf lessonslearnedfromenhancingvaccinepharmacovigilanceactivitiesduringpsattintroductioninafricancountries20102013 |